VTRS News and Press, Viatris Inc. From 04/22/24

2024-04-22 08:00:00 ET Summary 2023 was up 24%. 3 months down in 2024 and the S&P 500 is already up 6%, down from the plus 10% they were at. We are missing a few hundred in dividend income in March of this year, we normally would have had, but will be added to the April divide...

2024-04-17 09:26:31 ET More on CVS Health CVS Health: Seizing Opportunity Amid Recent Declines CVS Health: Good Management Is Keeping Their Promises CVS Health: Here Comes The Floor - Inherent Undervaluation Triggers Great Upside Potential Dividend Roundup: P...

Viatris to Report First Quarter 2024 Financial Results on May 9, 2024 PR Newswire PITTSBURGH , April 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its first quarter 2024 financial results on Thursday, May 9, 2024 , before the open ...

Viatris Appoints Corinne Le Goff as Chief Commercial Officer PR Newswire PITTSBURGH , April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial ...

Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada Canada NewsWire New generic Multiple Sclerosis treatment option, Pr Glatiramer Acetate Injection 20 mg/mL for once-daily injection, available for one of the larg...

2024-04-13 10:52:04 ET More on AbbVie, Amgen, etc. AbbVie: Bulletproof Fundamentals AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% UnitedHealth Q1 2024 Earnings Preview: Headwinds Not Enough To Derail This Juggernaut GLP-1s benefit Park...

2024-04-10 11:58:51 ET More on Estee Lauder, Hasbro, etc. Paramount Global's Sale Will Not Be Easy, Cheap, Or Fast Paramount: What The Skydance Proposal Means For Investors Paramount: Apollo Coming Around The Turn Ready To Pounce If Skydance Deal Falters ...

2024-04-09 05:49:33 ET Summary After nearly a decade of struggles, Perrigo is poised to turn the corner under the leadership of a new CEO who is only nine months in the seat. Infant formula woes will be resolved in Q2 and comparisons year over year will start to be favorable in th...

2024-04-08 17:01:16 ET Summary Viatris Inc. is a deep value pharmaceutical company with a low valuation and a 4.1% yield. Viatris has seen a slowdown in top line decline and has a promising pipeline of potential blockbuster drugs. Management is de-risking the balance sheet and...

2024-04-04 08:55:15 ET More on Viatris Viatris Stock Is Still Worth Buying Viatris Inc. (VTRS) R&D Event (Transcript) Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued Teva and Viatris revive chance to dispute J&J's schizophrenia dr...